Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function

Int J Impot Res. 2008 Jul-Aug;20(4):333-42. doi: 10.1038/ijir.2008.4. Epub 2008 Apr 17.

Abstract

Cyclic guanosine monophosphate (cGMP) in penile vascular smooth muscle cells (VSMC) plays a key role in promoting penile erection. Phosphodiesterase-5 (PDE5) in VSMC breaks down cGMP to counter this effect. Sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis), treatments for erectile dysfunction, inhibit PDE5 action. Many men with erectile dysfunction have improved erectile function after plasma inhibitor concentration falls below therapeutic levels. Maximum effect plus onset and duration of action of inhibitor determines its efficacy. The rate and extent of cellular drug accumulation and efflux of drug from smooth muscle cells plus persistence of drug effects in these cell impact these parameters. We propose possible molecular mechanisms that could account for prolonged action of PDE5 inhibitors including (1) persistence of biochemical effects after inhibitor is cleared from cells, and (2) retention of drug in VSMC beyond plasma clearance.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Cyclic Nucleotide Phosphodiesterases, Type 5 / metabolism
  • Erectile Dysfunction / blood
  • Erectile Dysfunction / drug therapy*
  • Erectile Dysfunction / enzymology*
  • Humans
  • Ligands
  • Male
  • Muscle, Smooth / drug effects
  • Phosphodiesterase 5 Inhibitors*
  • Phosphodiesterase Inhibitors / blood
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Time Factors

Substances

  • Ligands
  • Phosphodiesterase 5 Inhibitors
  • Phosphodiesterase Inhibitors
  • Cyclic Nucleotide Phosphodiesterases, Type 5